2001 Sep;3(3):229-36
Association of cardiometabolic multimorbidity with mortality
AST, ALT, GGT, and bilirubin
GIP receptor activation has been proposed, based on preclinical and early human data, to further support insulin secretion and fat metabolism, whilst glucagon receptor agonism may promote energy expenditure and reduce hepatic fat accumulation
Beware of counterfeit products, as they may cause serious adverse reactions Important safety considerations Patients taking retatrutide often experience common gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, and stomach pain
This is where GLP-1s step in, offering a glimmer of hope: 54 active clinical trials are currently exploring the use of GLP-1 Drugs in various conditions beyond diabetes and obesity